LONDON – Immunocore Ltd. has closed a series B round that will bring in more than $130 million, breathing fresh energy into its T-cell receptor programs in cancer and extending the reach of the technology into infectious and autoimmune diseases.
Neurovasc Technologies Inc., of Laguna Hills, Calif., has entered a strategic partnership with the Wego Group that includes $34 million in funding to support the company’s product portfolio development and global clinical trial program. Specifically, the funding first will go toward studies of the company’s stent-retriever, designed to treat patients suffering an acute ischemic stroke, in markets such as Japan, the EU, U.S. and China.
BEIJING – Chinese biosimilar maker Bio-Thera Solutions Ltd., of Guangzhou, on Feb. 21 launched a pre-revenue listing on Shanghai’s STAR market to reap $241 million at a valuation of almost $2 billion.
RSS
